HOME

WELCOME TO ADHERA THERAPEUTICS

formerly Marina Biotech. Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company’s commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.

Pill

Prestalia®

First FDA-approved, single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate. Prestalia® contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension, to lower blood pressure.

 

 

 

LEARN MORE

nucleic icon

Total Care™

Total Care™ is a Patient Centric Platform powered by Adhera’s DyrctAxess. Adhera Therapeutics integrates a series of assets and partnerships to deliver unparalleled support and convenience to chronic care patients.

 

LEARN MORE

DNA

Pipeline

Adhera Therapeutics has an exciting pipeline of additional drugs under development, that includes a next-gen Celecoxib that may prove to be an attractive option as an Opioid substitute.

 

LEARN MORE

 

Scroll Up